A number of research firms have changed their ratings and price targets for Tetraphase Pharmaceuticals (NASDAQ: TTPH):

  • 9/1/2017 – Tetraphase Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 8/30/2017 – Tetraphase Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
  • 8/28/2017 – Tetraphase Pharmaceuticals is now covered by analysts at Piper Jaffray Companies. They set an “overweight” rating and a $14.00 price target on the stock.
  • 8/22/2017 – Tetraphase Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/10/2017 – Tetraphase Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/9/2017 – Tetraphase Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $6.25 price target on the stock. According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
  • 7/27/2017 – Tetraphase Pharmaceuticals had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 7/26/2017 – Tetraphase Pharmaceuticals was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock, up previously from $8.00.
  • 7/26/2017 – Tetraphase Pharmaceuticals had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $13.00 price target on the stock, up previously from $12.00.
  • 7/11/2017 – Tetraphase Pharmaceuticals is now covered by analysts at HC Wainwright. They set a “buy” rating and a $15.00 price target on the stock.

Shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) traded up 3.15% during mid-day trading on Friday, hitting $6.88. 534,344 shares of the stock were exchanged. Tetraphase Pharmaceuticals, Inc. has a 12 month low of $3.11 and a 12 month high of $9.93. The stock’s 50 day moving average is $6.39 and its 200 day moving average is $7.22. The firm’s market cap is $351.24 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.76) by $0.07. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The firm had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $1.54 million. During the same period in the previous year, the business earned ($0.47) earnings per share. The business’s revenue for the quarter was up 28.2% on a year-over-year basis. Analysts expect that Tetraphase Pharmaceuticals, Inc. will post ($2.54) EPS for the current fiscal year.

In related news, insider Jacques Dumas sold 17,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total value of $105,000.00. Following the completion of the transaction, the insider now directly owns 17,500 shares of the company’s stock, valued at approximately $105,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.50% of the company’s stock.

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.